Comparative efficacy and acceptability of first-line single-agent chemotherapy in metastatic breast cancer.

e13082Background: The relative clinical outcomes associated with recommended first-line single-agent chemotherapy in metastatic breast cancer (MBC) is not clearly established. We aimed to comprehensively investigate the efficacy and safety of first-line single-agent chemotherapy in MBC patients. Methods: We searched for randomized clinical trials (RCTs) investigating randomized controlled trials (RCTs) that compared single-agent chemotherapy drugs containing: capecitabine, carboplatin, docetaxel, doxorubicin, epirubicin, gemcitabine, ixabepilone, liposomal-doxorubicin, mitozantrone, nanoparticle albumin-bound paclitaxel, paclitaxel or vinorelbine in MBC. Efficacy and toxicity were integrated by network meta-analyses. The PROSPERO registry number is CRD42018081185. Results: A total of 4,068 patients from 16 RCTs were included. Combining direct and indirect effects showed that different monotherapy regimens shared equivalent effect on overall survival and progression-free survival. However, compared with ge...